The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Heather Landau, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses data from the first 20 patients treated in the NEXICART-2 trial (NCT06097832), a Phase I/II dose escalation and expansion study of the BCMA-directed CAR T-cell therapy NXC-201 in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis. Dr Landau suggests that this CAR-T construct may potentially address a significant unmet clinical need, as she notes that no FDA-approved therapies exist in this patient population. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
